NDA 212888 · Viiv Hlthcare
Cabenuva Kit
Cabotegravir, Rilpivirine · Intramuscular
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Nov 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jan 21, 2021
Approved uses
8
Original approval plus efficacy supplements
Registered trials
97
26 Phase 3, 19 recruiting
FAERS reports
6,543
1,293 serious, 123 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 26, 2025.
CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine [see Microbiology ( 12.4 ), Clinical Studies ( 14.1 )] . CABENUVA, a 2-drug co-packaged product of cabotegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non‑nucleoside reverse transcriptase inhibitor (NNRTI), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV‑1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine. ( 1 )
Mechanism: CABENUVA contains 2 long-acting HIV-1 antiretroviral drugs, cabotegravir and rilpivirine [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 16, 2026 Supplement 18 · Efficacy LetterLabel
- Sep 20, 2024 Supplement 15 · Efficacy · priority review LetterLabel
- Mar 29, 2022 Supplement 6 · Efficacy · priority review LetterLabel
- Mar 29, 2022 Supplement 5 · Efficacy · priority review LetterLabel
- Mar 23, 2022 Supplement 3 · Efficacy LetterLabel
- Feb 7, 2022 Supplement 2 · Efficacy LetterLabel
- Jan 31, 2022 Supplement 1 · Efficacy LetterLabel
- Jan 21, 2021 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLetterLabelReview
2 products under this application
- CABENUVA KIT · CABOTEGRAVIR 400MG/2ML (200MG/ML); RILPIVIRINE 600MG/2ML (300MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
- CABENUVA KIT · CABOTEGRAVIR 600MG/3ML (200MG/ML); RILPIVIRINE 900MG/3ML (300MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cabotegravir" as an intervention, any sponsor and status, largest first.
- Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With MenPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02720094 · 4,570 participants · Start Dec 19, 2016 · Primary completion May 14, 2020
Drug: Cabotegravir Oral Tablet; TDF/FTC tablets and 4 more · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Oakland, California · 43 sites in all
- Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected WomenPivotal-lookingActive, not recruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT03164564 · 3,224 participants · Start Nov 7, 2017 · Primary completion Nov 5, 2020
Drug: Oral CAB; Oral TDF/FTC and 4 more · For: HIV Infections
Sites: Gaborone, Botswana; Mbabane, Eswatini; Kisumu, Kenya · 20 sites in all
- Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)Pivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT06134362 · 2,998 participants · Start May 14, 2024 · Primary completion Mar 14, 2029
Drug: CAB LA · For: HIV Infections
Sites: Almagro, Argentina; Buenos Aires, Argentina; Francistown, Botswana · 33 sites in all
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTPivotal-lookingRecruiting
Africa Health Research InstituteAcademic, hospital or other
NCT06250504 · 2,052 participants (planned) · Start Feb 27, 2024 · Primary completion Apr 30, 2026
Drug: APRETUDE (cabotegravir) 600 mg\3 mL; DAPIRING (Dapivirine) 25mg Vaginal Ring and 2 more · For: HIV Infections
Sites: Somkele, South Africa
- The Implementation of Pre-exposure Prophylaxis of Injectable CabotegravirPivotal-lookingStatus unknown
Evandro Chagas National Institute of Infectious DiseaseAcademic, hospital or other
NCT05515770 · 1,200 participants (planned) · Start Sep 20, 2022 · Primary completion Oct 2025
Drug: Cabotegravir Injection · For: HIV Infections
Sites: Rio de Janeiro, Brazil
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT03299049 · 1,049 participants · Start Oct 27, 2017 · Primary completion Jun 6, 2019
Drug: Cabotegravir Tablets; Rilpivirine Tablets and 2 more · For: HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Bakersfield, California · 119 sites in all
- SEARCH CAB LA Dynamic Choice HIV Prevention Study ExtensionPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT05549726 · 984 participants · Start Jan 2, 2023 · Primary completion Dec 18, 2023
Drug: Cabotegravir Injectable Suspension · For: HIV
Sites: Kisumu, Kenya; Mbarara, Uganda
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07682961 · 850 participants (planned) · Start Jul 14, 2026 · Primary completion Mar 2029
Drug: Lenacapavir; Lenacapavir Tablet and 4 more · For: HIV Infections
Sites: Bakersfield, California; Beverly Hills, California; Hidden Valley Lake, California · 61 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue722
- injection site pain669
- viral load increased514
- off label use478
- product use in unapproved therapeutic environment459
- virologic failure434
- pathogen resistance323
- pain304
- product complaint218
- exposure during pregnancy208
- injection site nodule203
- blood hiv rna increased197
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 205 |
| 2022 | 829 |
| 2023 | 1,276 |
| 2024 | 1,500 |
| 2025 | 1,515 |
| 2026 | 1,215 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
Landovitz RJ, Donnell D, Clement ME, et al. · N Engl J Med 2021 · Comparative Study, Equivalence Trial
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Equivalence Trial
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Equivalence Trial
- Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
Wang W, Zhao S, Wu Y, et al. · JMIR Public Health Surveill 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Delany-Moretlwe S, Hughes JP, Bock P, et al. · Lancet 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, et al. · Lancet HIV 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.